Good morning, you're listening to Markets Desk.
Galderma is making a significant move in the skincare space, announcing an all-cash deal to acquire ZO Skin Health for an enterprise value of one point five billion dollars. The Swiss dermatology company is betting that physician-grade skincare brands carry durable pricing power, expanding its portfolio beyond injectables into the broader prestige skincare market.
Shifting to pharma, Agomab Therapeutics has dosed its first patient in a global Phase two-b trial evaluating Ontunisertib for fibrostenosing Crohn's disease, a particularly difficult-to-treat form of the condition characterized by scarring and bowel narrowing. The milestone moves the company into mid-stage clinical territory for a disease with very limited treatment options, which is precisely why the market watches these readouts closely.
And on the macro side, Goldman Sachs is pushing back on a persistent narrative about Chinese exports. The bank argues Chinese companies are no longer competing on price alone — their consumer technology products are improving in quality and commanding higher price points over time, forcing global rivals into defensive price wars. That dynamic has real implications for margins across consumer electronics and beyond.
That's the tape. Markets Desk, signing off the floor.
